Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Treatment with Trastuzumab Deruxtecan for Metastatic HER2-Low Scrotal Extramammary Paget’s Disease Involving Bone Marrow: A Case Study

  • By

  • Yi Bao

  • Lei Zhang

  • Fenfen Jiang

  • Juanfen Mo

  • September 1, 2026

Share

  • 1

    Scrotal extramammary Paget’s disease (EMPD) can metastasize, as demonstrated in a case involving bone marrow infiltration.

  • 2

    The patient exhibited systemic manifestations, including pruritic scrotal lesions and impaired hematopoiesis due to tumor cell infiltration.

  • 3

    Histopathological assessments confirmed stage IV scrotal Paget’s disease with HER2 expression at 2+, but FISH testing was negative.

  • 4

    Treatment with trastuzumab deruxtecan (T-DXd) resulted in stable disease despite significant tumor burden.

  • 5

    This case highlights the aggressive nature of EMPD and the potential role of targeted therapies in managing low HER2 expression tumors.

Original Source(s)

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

  • by Yi Bao, Lei Zhang, Fenfen Jiang, Juanfen Mo

  • September 1, 2026

Related Content

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min